bilaterals.org logo
bilaterals.org logo

Intellectual property

Even before the World Trade Organization (WTO) lurched into its current state of crisis, bilateral FTAs had become a tool of choice for corporate and state interests seeking to expand intellectual property rights (IPR) standards. IPRs confer monopoly rights over intangible goods and services — methods of doing business on the internet, trademarks, computer programmes, designs, manufacturing processes, drug formulations or types of rice. They give IPR owners the right to prevent anyone from making or using their "creation". As such, they provide companies a direct tool to control a portion of the market, to block out competition and to fence off territories. Ironically, while IPR chapters are key aspects of many “free” trade and investment agreements, they are little more than protectionism for transnational corporations (TNCs), administered by governments. TNCs argue that without monopolies, there will be no innovation. Sharing should be banned; only capitalistic trade based on exclusive private property should be the norm.

Through FTAs, bilateral investment treaties (BITs) and other forms of direct agreements between countries, the US and Europe are insisting that the partner country adopt their standards of IPR protection and enforcement. This process has happened multilaterally via the WTO and the World Intellectual Property Organization. But it is now being pushed very aggressively through unilateral, bilateral and regional agreements — deals which go much further than the WTO’s Agreement on Trade-Related aspects of Intellectual Property rights (TRIPs). FTAs are setting “TRIPs-plus” standards.

The US imposes patents on plants and animals in its FTAs, while the EU and Japan, for the benefit of their biotech companies, push the UPOV Convention, a set of patent-like rules to prevent farmers from saving seeds. Meanwhile, pharmaceutical corporations have turned to FTAs as tools to impose stricter rules preventing the manufacture and trade of generic drugs. For many countries, and many peoples, these propositions are nothing short of revolutionary. Because it means they have to

 extend protection for branded drugs and limit parallel imports, hampering the availability of affordable generic medicines
 start patenting plants and animals, which means farmers cannot save seed or reproduce fish breeds or livestock
 get rid of screen quotas that give preference to the showing of local films
 start patenting computer software, to the detriment of local programmers and the creative open source movements now mushrooming up across the world as a cheaper alternative to Microsoft
 extend copyright protection, which already causes serious problems for students, libraries and educational institutions
 clamp down on piracy of popular consumer goods like digital products, clothing and music
 make IPR infringements criminal offences, even though IPR is part of civil law
and the list goes on.

Through IPRs, corporations seek monopoly control over vast areas of life. They expect that we should all regularly pay them licenses to use their products and to reimburse their research and development costs. Never mind all the public subsidies, tax breaks, university contract labour and so on that go into their research and development in the first place. IPR laws being pushed through bilateral channels make it public policy that countries should protect the TNCs, the real pirates.

Because of the serious implications that ‘TRIPs-plus’ IPR chapters of FTAs have for broad cross-sections of societies, in some anti-FTA struggles, such as the fightback against the US-Thailand FTA, farmers and people living with HIV/AIDS have joined together in their opposition of this new threat to their survival. Concerns have also been raised about the way in which the EU’s EPAs include TRIPs-plus provisions, while Indigenous Peoples in many countries continue to assert alternative frameworks for the use and sharing of traditional knowledge that challenge the capitalist, commodified logic of “intellectual property rights” enshrined in free trade and investment agreements.

More recently, a new development in transnational IPR enforcement has sparked opposition and controversy, including major protests in many European cities. In October 2011, after a secretive negotiations process, the Anti-Counterfeiting Trade Agreement (ACTA) was signed by a number of countries and will come into effect once six countries have ratified it. ACTA would potentially set up a new international legal framework for enforcing IPR. Opponents have criticized the agreement’s impact on privacy, freedom of expression and internet freedoms, and generic drug manufacturing.

last update: May 2012

Photo: Chile Mejor Sin TLC


South American Ministers vow to avoid TRIPS-plus measures
The Ministers of Health of ten South American countries issued a joint declaration on intellectual property committing themselves to avoid "TRIPS plus" provisions in bilateral and regional trade agreements, to facilitate the use of compulsory licensing and parallel importing and to avoid broadening the scope of patentability and the extension of patentable areas.
The treatment of geographical indications in recent regional and bilateral FTAs
The objective of this paper is to analyze what has been the treatment of GIs in the new generation of regional trade agreement as well as the content of the new standards being set.
Trade-related intellectual property rights, access to medicines and human rights - Morocco
The briefing calls for an independent human rights impact assessment of the effect of intellectual property rules in the US-Morocco Free Trade Agreement (FTA) on access to medicines and the enjoyment of human rights in Morocco.
US pushes to limit generic drug rights
Under global trading rules, the inventors of medicines ordinarily enjoy the right to a 20-year monopoly on their inventions. But five years ago, the United States joined 141 other countries to sign the Doha Declaration, confirming the right of poor countries to break drug patents and produce cheap generic drugs in the event of contagions like HIV.
The impact of free trade agreements on intellectual property standards in a post-TRIPS world
We are living in a post-TRIPS (Trade-Related Aspects of Intellectual Property Rights) world. Almost every member of the World Trade Organization (WTO) has had to reform their intellectual property laws in order to meet the minimum standards of protection that TRIPS prescribes .
The US-Peru Trade Promotion Agreement (TPA): The intellectual property provisions
Report of the US government’s Industry Trade Advisory Committee on Intellectual Property Rights (ITAC-15)
FTAs: Trading away traditional knowledge
Traditional knowledge has come up in a dozen or so FTA drafting processes over the last couple of years. In half of those cases, specific provisions on traditional knowledge were signed.
Intellectual property provisions of bilateral and regional trade agreements in light of US federal law
The critical lesson for developing countries accepting IPRs commitments in FTAs with the United States is that US IPRs law is replete with exceptions to the general rules, in many cases elaborated in considerable detail. If developing countries accept obligations in the FTAs, they must also be prepared to implement a significant level of exceptions so as to create a reasonable balance within their own law. If they do not implement these exceptions, they will find themselves not only with TRIPS-plus levels of IPRs protection, but also with US-plus levels of IPRs protection.
Tripping up TRIPs debates
Access to medicine is at the forefront of multilateral debates surrounding the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs). This paper argues that bilateralism allows the United States to circumvent these debates and to set standards that serve and protect the pharmaceutical industry.
EDITORIAL: Health at stake in free-trade talks
For the United States, intellectual property rights represent the single most valuable asset in light of the new reality of information-based economies and where they derive their national wealth. The supremacy of the US as a global power depends on how effective it is in acquiring and maintaining its ownership of knowledge assets.